8 results about "Proteasome activity" patented technology

The application discloses application of leucyl phenylalanine in preparation of a medicine for Parkinson's disease. Specifically, it is found that leucyl phenylalanine can relieve dopamine neuron dendrite degeneration of a Caenorhabditis elegans model of Parkinson's disease, enhance autophagy level, and improve proteasome activity, thereby providing an effective treatment scheme for treating Parkinson's disease.

The invention provides a plant extract for promoting metabolism as well as a supercritical extraction method and application thereof, and relates to the technical field of cosmetics. The plant extract is composed of a geranium wilfordii extract, a juniper berry extract and a sea buckthorn fruit extract, after geranium wilfordii leaves are subjected to enzymolysis with compound enzyme, graded supercritical extraction is conducted, and the geranium wilfordii extract is obtained; performing quick-freezing and freeze-drying on fresh juniper berries, and performing supercritical extraction to obtain juniper berry extract; performing subcritical ultrasonic extraction on the dried sea buckthorn fruits to obtain the sea buckthorn fruit extract, and mixing the three to obtain the plant extract. The three extracts show a remarkable synergistic effect in the aspects of promoting skin metabolism and resisting inflammation, and can activate cell energy metabolism, improve microcirculation and promote tissue repair and regeneration. Cell and animal experiments prove that the composition can remarkably improve proteasome activity and inhibit inflammatory response, can be applied to cosmetics and is used for preparing skin care products with the effects of promoting metabolism, improving skin quality, resisting inflammation and relieving.

Disclosed in the present invention are a peptide epoxyketone compound, a preparation method therefor, and a use thereof. The structural formula of the peptide epoxyketone compound is as shown in I. The compound or a pharmaceutically acceptable salt thereof can selectively inhibit the activity of an immunoproteasome, and thus can be used for developing drugs for treating various autoimmune diseases in humans and animals.

The invention belongs to the field of medicines, and discloses an antibody conjugate, the antibody conjugate is obtained by coupling a connecting structure, bortezomib and an antibody, the antibody conjugate has extremely strong drug sensitivity, and when the antibody conjugate is singly used or combined with cis-platinum, the antibody conjugate shows a remarkable inhibition effect on activity of proteasomes in MDA-MB-231 cells and mouse tumors. Meanwhile, the invention also discloses application and a medicine based on the antibody conjugate.

The invention discloses a compound with proteasome agonist activity and a preparation method and application thereof.The structural general formula of the compound is shown in the specification, and the compound is a 20S proteasome agonist. According to the preparation method, phthalic acid and derivatives thereof serve as starting raw materials, and the compound with the proteasome agonist activity is obtained through an efficient synthesis route. A series of compounds with proteasome agonistic activity are prepared. Experiments prove that the target compound provided by the invention shows remarkable 20S proteasome agonistic activity. Therefore, the compound has a wide application prospect in the aspect of treating diseases related to insufficient 20S proteasome activity and dysstable protein homeostasis.

The present application relates to a kind of light-enhanced carrier-free tumor vaccine and its preparation method and application, belong to tumor immunotherapy technical field.The light-enhanced carrier-free tumor vaccine is prepared by the precipitation of photosensitizer and immunoadjuvant in antigen protein / polypeptide cavity.The vaccine is drained to lymph node after subcutaneous administration or incubated with antigen presenting cells such as dendritic cells, and can produce singlet oxygen under light to destroy lysosome, promote intracellular transport of tumor antigen and immunoadjuvant, and enhance proteasome activity, enhance tumor antigen presentation, induce CD8 + T cell-mediated anti-tumor immune response.Therefore, the vaccine can be prepared by extracting antigen from tumor tissue removed by surgery, achieve individual customization, and can be used with PD-L1 antibody, etc., has the effects of prevention, treatment and prevention of recurrence, has the advantages of high drug loading, high safety, time and space controllable light-enhanced immune activation characteristics and one-to-one personalized treatment.

The application discloses an anti-tumor traditional Chinese medicine composition, a preparation method thereof and application of the anti-tumor traditional Chinese medicine composition in preparation of a synergist of a PD-1 inhibitor. The anti-tumor traditional Chinese medicine composition comprises ginsenoside Rg1 and atractylenolide-I, and the mass ratio of the ginsenoside Rg1 to the atractylenolide-I is 4:1-1:4. The composition can further comprise a drug carrier and a surface modification material. In the composition, the ginsenoside Rg1 can regulate the MVA pathway of the normal metabolism of dendritic cell cholesterol, and enhance the antigen presentation capacity of the dendritic cells; the atractylenolide-I can enhance the activity of the immunoproteasome of tumor cells, and then up-regulate the MHC-I expression of the tumor cells. The drug carrier can efficiently co-load the anti-tumor traditional Chinese medicine composition, and the surface modification material can realize the in-vivo Ly6C + macrophage transport of the preparation to the central region of tumor tissues. The anti-tumor traditional Chinese medicine composition of the application can significantly promote the infiltration of T lymphocytes to tumor tissues and recognize and kill tumors, and the combination with the PD-1 inhibitor can significantly improve the anti-MSS type colorectal cancer effect of the PD-1 inhibitor.